Merck Earnings ESP and Zacks Rank Signal Likely Beat Before April 30

The pharmaceutical giant (Market Cap: $316.79B) operates within the Zacks Large Cap Pharmaceuticals industry, where consistent performance is closely monitored. Merck has delivered earnings beats in the recent past, with the last two quarters producing an average surprise of 4.91%.

In the most recent quarter, the company exceeded the EPS estimate of $2.03, reporting $2.04 per share for a 0.49% surprise. This adds to the prior quarter’s performance, where a $2.58 actual EPS beat the $2.36 consensus by 9.32%. The current positive Earnings ESP of +3.14% suggests analysts have recently revised their expectations upward, indicating potentially more accurate near-term forecasts.

Stocks exhibiting a positive Earnings ESP alongside a Zacks Rank of #3 (Hold) or better have historically achieved a surprise nearly 70% of the time. This statistical mechanism highlights the relevance of recent analyst revisions captured in the Most Accurate Estimate compared to the broader consensus. Merck’s trajectory suggests the upcoming report on April 30, 2026, could continue the streak.

What to watch next is the actual EPS figure released on April 30, 2026, to confirm if the positive indicator translates into another beat.